Trading halted as Radient Pharmaceuticals Receives NYSE Amex Approval for Debt to Equity Exchange

Print E-mail
By Staff and canada viagra Wire Reports   
Friday, 07 January 2011 09:50
Shares of Radient Pharmaceuticals Corporation (AMEX:RPC) were halted by officials this morning.


Over 1 million shares had traded hands during pre-market hours this morning before Amex officials halted trading in the cialis 30 mg stock. The company specializing in the research, development, and international commercialization of In Vitro Diagnostic cancer tests, announced today it has received approval from the buy cialis on line New York Stock Exchange AMEX to issue RPC common stock pursuant to proposals approved by RPC's shareholders on December 3, 2010.

According to RPC Chairman and cialis online pharmacy CEO Douglas MacLellan, "We are pleased with the cialis non prescription NYSE Amex approval and viagra on line believe this sets the canada meds viagra Company and cialis india pharmacy on a solid path for the future growth and usa cialis financial stability. Based upon shareholder and soft cialis NYSE Amex approval of the various note transactions, warrant conversions and buy cialis online canada debt exchange agreements, RPC is in a position to have up to approximately $27 million in debt and cialis profesional $14 million in other liabilities eliminated. As a result, we anticipate an increase of approximately $41 million in total shareholder's equity."

BioMedReports ran a special report about the company this morning.

It can be found here: http://biomedreports.com/2011010762156/radient-positioned-to-deliver-significant-cancer-test-profits.html





BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 
BioMedReports Tight blood sugar control doesn't prevent strokes in diabetics http://t.co/LnOYmPJrb7
BioMedReports Healthcare Review: Cerner Corporation, PharMerica Corporation, Aratana Therapeutics, Novartis, Horizon Pharma:... http://t.co/eMjdl6x76n
BioMedReports Vivus's ED Drug Marketing Approved; Auxilium Pharma Reports XIAFLEX Data from Multicord: Below is a look at so... http://t.co/Y27UqYyxD0
navigation
Benzinga.com supporter Seeking Alpha Certified